6 citations
,
April 2010 in “Arthritis Care & Research” Antituberculous drugs improved symptoms in a woman with lupus and myositis.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
18 citations
,
June 2017 in “Oncotarget” Digoxin is linked to a higher risk of anemia in patients with atrial fibrillation and heart failure.
1 citations
,
July 2025 in “Functional Foods in Health and Disease” CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
November 2003 in “PubMed”
18 citations
,
January 1999 in “CNS Drugs” Some anticonvulsant drugs can cause skin reactions, ranging from mild to severe, and managing these reactions is important for patient care.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference”
15 citations
,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
5 citations
,
January 2010 in “Medicinal Plants - International Journal of Phytomedicines and Related Industries” Tridax procumbens has medicinal properties.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
June 2014 in “Reactions Weekly”
104 citations
,
January 2005 in “Climacteric” Drospirenone is a unique progestin with anti-water retention and potential blood pressure benefits, used in birth control and hormone therapy.
January 2014 in “Reactions Weekly”
31 citations
,
June 2015 in “British Journal of Dermatology” Hormonal treatments are effective as a second-line option for moderate-to-severe acne in females, but should be used with caution due to health risks.
August 2011 in “Reactions Weekly”
October 2025 in “Infection Control and Hospital Epidemiology” Standardized protocols are crucial for safe and infection-free platelet-rich plasma therapy.
May 2026 in “Reactions Weekly” April 2026 in “Reactions Weekly” December 2024 in “Reactions Weekly” November 2014 in “Reactions Weekly” July 2014 in “Reactions Weekly” August 2013 in “Reactions Weekly” January 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly”